文献速递浆细胞疾病造血干细胞移植与细胞治疗

多发性骨髓瘤自体移植后MRD阴性预测因素及临床结局

Predictors of posttransplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma.
PubMed 文献 · Blood Adv · 2026-01-01

研究纳入814例自体移植后达≥非常好的部分缓解的多发性骨髓瘤患者,48%实现MRD阴性;t(11;14)和移植前未达完全缓解独立预测MRD阳性;MRD阳性者PFS和OS更差,但t(11;14)阳性者MRD阴性率虽低,5年PFS与MRD阴性者相似。

要点

  • 自体移植后48%患者实现MRD阴性,t(11;14)和移植前<CR独立预测MRD阳性。
  • MRD阳性者PFS(HR 1.99)和OS(HR 1.62)均劣于MRD阴性者。
  • t(11;14)阳性者即使MRD阳性,5年PFS与MRD阴性者相似(58% vs 63%)。

核心结论

  • t(11;14)独立预测ASCT后MRD阳性,但不显著影响该亚组预后。
  • MRD阳性者PFS和OS更差,且高危细胞遗传学异常数量影响PFS。

研究设计与样本

  • 回顾性研究纳入2016年1月至2023年1月间814例ASCT后达≥VGPR并接受二代流式MRD评估的多发性骨髓瘤患者。

主要发现

  • 387例(48%)ASCT后实现MRD阴性。

临床怎么用

  • ASCT后应评估MRD状态,MRD阳性提示预后不良。
  • 对于t(11;14)患者,MRD阳性并不显著影响预后,需结合其他因素判断。
  • MRD阳性患者中,高危细胞遗传学异常数量和残留克隆浆细胞负荷可进一步分层PFS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) is a powerful prognostic tool in multiple myeloma, but predictors of achieving MRD negativity after autologous stem cell transplantation (ASCT) are not well defined. We studied 814 patients who achieved at least a very good partial response after ASCT between January 2016 and January 2023 and underwent MRD assessment by next-generation flow cytometry. Overall, 387 (48%) achieved MRD negativity after ASCT. The presence of t(11;14) (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.4-3.2; P< .01) and pretransplant response less than complete remission (OR, 2.1; 95% CI, 1.2-3.7; P< .01) independently predicted MRD positivity. Patients who were MRD positive had inferior progression-free survival (PFS; hazard ratio [HR], 1.99; 95% CI, 1.53-2.58; P< .001) and overall survival (HR, 1.62; 95% CI, 1.10-2.28; P = .009). Despite lower MRD-negative rate, 5-year PFS was similar among t(11;14) MRD positive (58%) and patients who were MRD negative (63%; P = .12). In patients who were MRD negative, the 5-year PFS was 73% in those without ≥2 HRCA compared with 55% in those with ≥2 HRCA (HR 1.9, 95% CI 1.2-3.3; P = .01). In the MRD-positive cohort, 5-year PFS was 53% in patients without ≥2 HRCA vs 17% in those with ≥2 HRCA (HR, 2.4; 95% CI, 1.6-3.6; P< .01). In addition, higher residual clonal plasma cell burden within MRD-positive disease was associated with inferior PFS (HR, 2.4; 95% CI, 1.2-6.9; P = .002). This study highlights that the presence of t(11;14) independently predicts MRD positivity after ASCT, although it does not significantly affect prognosis in this subgroup.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bolarinwa A, Zanwar S, Abdallah N, et al. Predictors of posttransplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma. Blood Adv. 2026. PMID: 42508994. doi:10.1182/bloodadvances.2026020294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。